ScreenerHero
AMRXAmneal Pharmaceuticals, Inc.
NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · amneal.com
17.88USD-0.11%Mkt Cap: 6.23B $P/E: 37.29

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, I…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap6.23B $
Enterprise Value8.46B $
Revenue (TTM)3.12B $
Gross Profit1.11B $
Net Income (TTM)72.06M $
Revenue/Share9.866 USD
Last Price17.88 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8.7K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS03168L1052
Valuation
P/E (Trailing)37.29
P/E (Forward)14.91
PEG—
EV/EBITDA12.27
EV/Revenue2.71
P/S2.00
P/B173.79
EPS (TTM)0.47
EPS (Forward)1.20
52W Range
8.21088% of range19.26
52W High19.26 USD
52W Low8.210 USD
Profitability
Gross Margin36.88%
Oper. Margin18.34%
EBITDA Margin22.12%
Profit Margin2.39%
ROE-101.78%
ROA1.96%
Growth
Revenue Growth9.90%
Earnings Growth157.10%
Cash Flow & Leverage
Operating CF339.99M $
CapEx (TTM)114.36M $
FCF Margin-3.70%
FCF Yield-1.85%
Net Debt2.66B $
Net Debt/EBITDA3.86
Balance Sheet
Debt/Equity-37.98
Current Ratio2.21
Quick Ratio1.38
Book Value/Sh0.1030 USD
Cash/Share0.4110 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)20.75 USD
Upside (mean)+16.1%
Target Range16.00 USD – 25.00 USD
$16.00+16.1% to mean$25.00
# Analysts4
Ownership
Shares Out.348.30M
Float186.06M
Insiders52.17%
Institutions48.42%
Short Interest
Short Ratio4.5d
Short % Float3.85%
Short % Out.2.61%
Shares Short8.32M
Short (prev mo.)7.84M
Technical
SMA 5017.46 (+2.4%)
SMA 20014.03 (+27.4%)
Beta1.25
S&P 52W Chg18.16%
Avg Vol (30d)1.80M
Avg Vol (10d)1.82M
Technical Indicators
RSI (14)52.4
MACD0.2959
MACD Signal0.4373
MACD Hist.-0.1415
BB Upper19.13 USD
BB Middle18.14 USD
BB Lower17.14 USD
BB Width10.99%
ATR (14)0.7060 USD
Vol Ratio (20d)0.54x